Pharmacokinetics and cardiopulmonary effects in dogs of sublingual pirbuterol, a new bronchodilator.
The time course of plasma concentrations of sublingually administered pirbuterol was investigated in anesthetized dogs; there was a dose-related increase in plasma drug concentrations which reached maximum values 1 hr or more after administration. In a second study plasma drug levels were correlated with antagonism of histamine-induced changes in pulmonary compliance and resistance which also reached maximum values 1 hr or more after drug administration, although marked antagonism was apparent at 15 to 30 min; blood pressure was unaltered at any dose level and heart rate was influenced only at the highest dose level. A convenient method for study of the bioavailability of sublingual formulations is described, and the potential usefulness of a sublingual dosage form of pirbuterol is discussed.
D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D001682:Biological Availability; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D004285:Dogs; D004983:Ethanolamines / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D007700:Kinetics; D008297:Male; D009060:Mouth Floor; D011725:Pyridines / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D012119:Respiration / Q000187:drug effects*; D013607:Tablets
D001993:Bronchodilator Agents; D004983:Ethanolamines; D011725:Pyridines; D013607:Tablets; C009118:pirbuterol